| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTLA | Common Stock | Options Exercise | $362K | +27K | +1129.23% | $13.40 | 29.4K | Aug 30, 2021 | Direct | |
| transaction | NTLA | Common Stock | Options Exercise | $998K | +70K | +238.17% | $14.25 | 99.4K | Aug 30, 2021 | Direct | |
| transaction | NTLA | Common Stock | Sale | -$2.42M | -15.8K | -15.94% | $152.75 | 83.6K | Aug 30, 2021 | Direct | F1, F2 |
| transaction | NTLA | Common Stock | Sale | -$3.17M | -20.6K | -24.71% | $153.64 | 62.9K | Aug 30, 2021 | Direct | F1, F3 |
| transaction | NTLA | Common Stock | Sale | -$4.44M | -28.7K | -45.57% | $154.77 | 34.2K | Aug 30, 2021 | Direct | F1, F4 |
| transaction | NTLA | Common Stock | Sale | -$2.51M | -16.1K | -47.07% | $155.61 | 18.1K | Aug 30, 2021 | Direct | F1, F5 |
| transaction | NTLA | Common Stock | Sale | -$1.16M | -7.43K | -40.97% | $156.79 | 10.7K | Aug 30, 2021 | Direct | F1, F6 |
| transaction | NTLA | Common Stock | Sale | -$620K | -3.93K | -36.75% | $157.77 | 6.77K | Aug 30, 2021 | Direct | F1, F7 |
| transaction | NTLA | Common Stock | Sale | -$241K | -1.52K | -22.39% | $158.90 | 5.25K | Aug 30, 2021 | Direct | F1, F8 |
| transaction | NTLA | Common Stock | Sale | -$424K | -2.65K | -50.52% | $159.64 | 2.6K | Aug 30, 2021 | Direct | F1, F9 |
| transaction | NTLA | Common Stock | Sale | -$33.2K | -207 | -7.97% | $160.47 | 2.39K | Aug 30, 2021 | Direct | F1, F10 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTLA | Stock Option (right to buy) | Options Exercise | $0 | -27K | -24.77% | $0.00 | 82K | Aug 30, 2021 | Common Stock | 27K | $13.40 | Direct | F11 |
| transaction | NTLA | Stock Option (right to buy) | Options Exercise | $0 | -70K | -46.67% | $0.00 | 80K | Aug 30, 2021 | Common Stock | 70K | $14.25 | Direct | F12 |
| Id | Content |
|---|---|
| F1 | The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.16 to $153.155, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.16 to $154.15, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.22 to $155.215, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.22 to $156.19, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.22 to $157.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.305 to $158.245, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.31 to $159.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $160.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F10 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.40 to $160.53, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. |
| F11 | The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 30, 2021. |
| F12 | The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 84,375 shares as of August 30, 2021. |